GlobeNewswire

Datameer Achieves Advanced Technology Partner Status in the Amazon Web Services Partner Network and Launches Datameer Express on AWS Marketplace

Dela

SAN FRANCISCO, July 11, 2018 (GLOBE NEWSWIRE) -- Datameer, a leader in big data management for analytics, is pleased to announce that it has achieved Advanced Technology Partner status in the Amazon Web Services (AWS) Partner Network (APN). In addition, Datameer Express is now available on AWS Marketplace, allowing organizations to leverage AWS to simplify their management of data for analytics. Datameer Express provides the accessibility, flexibility, and simplicity of AWS and allows enterprises to be up and running in less than 30 minutes.

Datameer Express is an analytics data management platform that natively leverages AWS to deliver faster time to insight without the need to code or integrate disparate tools. Datameer covers the full data lifecycle from integration to preparation to exploration, and works with any data source, and with any Business Intelligence (BI) or data science tool. It simplifies and accelerates the time-consuming, cumbersome process of turning complex, multi-source data into valuable business-ready information to drive greater business agility. Availability of Datameer Express on AWS Marketplace helps enterprises eliminate the burden of turning complex and dispersed data into business-ready information by leveraging Datameer and migrate more workloads to AWS services like Amazon Simple Storage Service (Amazon S3) and Amazon Elastic Compute Cloud (Amazon EC2).

"We're excited to continue advancing our relationship with AWS and give customers access to Datameer directly from AWS Marketplace, where leading global organizations are modernizing and transforming their analytics infrastructures," said Claudine Lagerholm, Vice President, Strategic Partnerships at Datameer. "We're proud to be an APN Advanced Technology Partner as more of our customers continue moving to the cloud. Making Datameer available on AWS Marketplace simplifies the deployment and procurement process for companies looking to leverage all their data for faster, better decision-making, and AWS delivers the cost-effectiveness, agility, and flexibility they need."

Datameer Express on AWS
Datameer Express takes the rich data preparation, integration and exploration features of Datameer, and packages it into an easy deployment and consumption model on AWS. Datameer Express works with key AWS services to provide a higher level streamlined and secure platform to create and manage powerful data pipelines to fuel cloud-based analytics. Datameer Express can consume data from Amazon S3, Amazon Redshift, Amazon Aurora and other cloud data sources, integrate with on-premises data sources, and create result sets that can be delivered into Amazon Redshift and other cloud data warehouses, or consumed by Amazon Athena and Amazon QuickSight.

Datameer Express enables companies to empower business analysts to take control and deliver their own personalized analytic data pipelines for any analytics initiative. It facilitates faster, agile data pipelines to feed cloud data warehouses for faster, expandable analytics, derive more value from Amazon S3 data lakes, or drive new innovations in machine learning and artificial intelligence.

Pricing and Availability
Pricing for Datameer Express, which is available immediately, offers hourly and annual pricing models starting at $4.79 per hour. Datameer will be at AWS Summit New York, July 17 at Jacob K. Javits Convention Center (8:00am - 5:00pm). AWS Global Summits are free events designed to bring together the cloud computing community to connect, collaborate, and learn about AWS.

About Datameer
Datameer is changing the way companies do business by enabling them to get value and insights from their data at the speed of thought to make better, more trustworthy decisions and drive better business outcomes. Datameer offers a unified way to simplify the time-consuming, cumbersome process of turning complex, multi-source data into valuable, business-ready information in a matter of minutes and hours, rather than weeks or months. Leading global organizations, including Citibank, Royal Bank of Canada, Aetna, Optum, HSBC, National Instruments, Vivint and more use our secure and scalable enterprise-grade platform to streamline and simplify data integration, preparation and exploration so subject matter experts can leverage trusted data to cultivate innovation, creativity and efficiency for competitive advantage. Learn more at www.datameer.com and follow us on Twitter at @Datameer.

Samantha Leggat
samantha.leggat@datameer.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Datameer via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum